India Pharma Outlook Team | Wednesday, 17 September 2025
Mankind Pharma, the fourth-largest pharmaceutical company in India, has announced a strategic partnership with OpenAI as it looks to institutionalize AI across its value chain.
As a result, Mankind is now one of the first Indian pharmaceutical companies to integrate advanced AI into its core operations, representing a significant step forward for the industry.
The collaboration will bring in OpenAI Enterprise across a range of functions including field force enablement, digital marketing, R&D, manufacturing and medical affairs. By embedding ChatGPT Enterprise as well as new models like GPT-5, the company is looking for faster innovation, regulatory compliance, and smarter and faster decision-making.
Also Read: Designing Packaging Systems for Regulatory Compliance and Quality
Arjun Juneja, chief operating officer, Mankind Pharma Ltd. said "We see working with OpenAI as a pivotal step in building the pharma organization of the future…new benchmarks for how technology can drive both operational excellence and long-term value creation."
Since July 2025, the company has been deploying custom GPTs throughout its workforce delivering measurable impact in sales and marketing. These tools are enabling sharper messaging, multilingual communications, improved demand planning, procurement optimisation, and commercial operations performance. The field force can now be monitored on a real time basis, along with predicting clinical insights in a more predictable and reliable manner in manufacturing processes.
“The company-wide adoption of ChatGPT Enterprise shows the practical role AI can play in regulated industries such as pharmaceuticals. By integrating advanced AI… responsibly and safely to deliver value within their organization and across the healthcare ecosystem,” said Oliver Jay, managing director, International, OpenAI.
